Genetec (TSE:4492) EBIT: 円857 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4492 Genetec Corp TSE:4492
77 GF Score
Price 円412.00
GF Value 円758.81
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genetec EBIT?

Genetec TSE:4492 -0.72% 77 EBIT is 円857 Mil as of Mar. 2026. GuruFocus rates TSE:4492 with a GF Score™ of 77/100 and a GF Value™ of 円758.81 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Genetec's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円679 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円857 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genetec's annualized ROC % for the quarter that ended in Mar. 2026 was 18.91%. Genetec's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 71.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Genetec's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 16.35%.

Genetec  (TSE:4492) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genetec's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1336.846 * ( 1 - 35.94% )/( (4567.531 + 4491.121)/ 2 )
=856.3835476/4529.326
=18.91 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6474.962 - 657.754 - ( 1661.772 - max(0, 2786.013 - 4035.69+1661.772))
=4567.531

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6912.112 - 947.662 - ( 1597.62 - max(0, 3017.564 - 4490.893+1597.62))
=4491.121

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Genetec's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1358.242/( ( (858.578 + max(772.963, 0)) + (907.461 + max(1277.064, 0)) )/ 2 )
=1358.242/( ( 1631.541 + 2184.525 )/ 2 )
=1358.242/1908.033
=71.19 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1632.185 + 224.325 + 240.886) - (657.754 + 0 + 666.679)
=772.963

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2289.349 + 185.759 + 267.568) - (947.662 + 0 + 517.95)
=1277.064

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Genetec's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=857.442/5244.496
=16.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetec EBIT Related Terms

Genetec EBIT Historical Data

* Premium members only.

The historical data trend for Genetec's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetec EBIT Chart

Genetec Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only 117.62 91.35 636.74 673.27 857.44

Genetec Semi-Annual Data
Mar18 Mar19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 435.75 342.14 331.13 178.32 679.12

TSE:4492 vs UBER, SHOP, CRM: EBIT Comparison

For the Software - Application subindustry, Genetec's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetec EV-to-EBIT vs Software Industry

For the Software industry and Technology sector, Genetec's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genetec's EV-to-EBIT falls into.


TSE:4492
77GF Score
Genetec Corp TSE:4492
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetec EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円857 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円857 Mil mean?
Genetec (TSE:4492) has a EBIT of 円857 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Genetec.
Is Genetec's EBIT too high?
Genetec's current EBIT is 円857 Mil. Overall, Genetec has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetec's EBIT compare to UBER and SHOP?
Genetec's EBIT of 円857 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Software company?
A good EBIT depends on the Software industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Genetec. Genetec's current EBIT is 円857 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetec stock overvalued right now?
Based on GuruFocus' analysis, Genetec (TSE:4492) is currently considered Significantly Undervalued. The stock's GF Value™ is 円758.81, compared to a current price of 円412.00 — trading 45.7% below its estimated fair value. The current EBIT is 円857 Mil. Genetec's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Genetec (TSE:4492), the current EBIT is 円857 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetec (TSE:4492) Overvalued in 2026?

Based on GuruFocus' analysis, Genetec stock appears to be undervalued. The current stock price of 円412.00 is trading 45.7% below its estimated GF Value™ of 円758.81. GuruFocus considers Genetec to be Significantly Undervalued.

Key valuation signals for TSE:4492:

  • EBIT: 円857 Mil
  • GF Value™: 円758.81 vs. price of 円412.00 (45.7% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the TSE:4492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genetec Business Description

Address 6-5-1 Nishi-Shinjuku, Shinjuku-ku, Shinjuku Island Tower 25th Floor, Tokyo, JPN, 163-1325
Genetec Corp is engaged in the provision of system development, engineering, and IOT/cloud solutions. Its services include software development, hardware development, engineering solutions, Mastercam, Robomaster, flexisim, IoT/M2M business, surve-I, Coco Dayo, and web integration.
77GF Score

Get the complete analysis for TSE:4492

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円412.00
Price
円758.81
GF Value